The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Open accessAbstract
Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and conventional treatments have little impact on survival. Therapeutically, this tumor is poorly responsive, largely due to drug resistance. Accumulating evidence suggest that this chemoresistance is intimately linked to specific metabolic aberrations of pancreatic cancer cells, notably an increased use of glucose and the amino acid glutamine fueling anabolic processes. Altered metabolism contributes also to modulation of apoptosis, angiogenesis and drug targets, conferring a resistant phenotype. As a modality to overcome chemoresistance, a variety of experimental compounds inhibiting key metabolic pathways emerged as a promising approach to potentiate the standard treatments for pancreatic cancer in preclinical studies. These results warrant confirmation in clinical trials. Thus, this review summarizes the impact of metabolic aberrations from the perspective of drug resistance and discusses possible novel applications of metabolic inhibition for the development of more effective drugs against pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Duxbury, M. S., Ito, H., Benoit, E., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Surgery · doi:10.1016/j.surg.2004.04.029 · Cited by 52
RetractedLai, I., Chou, C.-C., Lai, P.-T., Fang, C., Shirley, L. A., Yan, R., Mo, X. M., Bloomston, M., Kulp, S. K., Bekaii‐Saab, T., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu124 · Cited by 38
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“High throughput sequencing and copy number studies of PDAC genome have identified and validated the known driver mutations in K-RAS, TP53, CDKN2A, and SMAD4, as well as novel gene mutations that may be involved in cell growth, DNA repair, invasiveness, angiogenesis and metabolism.(31) These studies can”
BackgroundCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Lactate: A Metabolic Key Player in Cancer
Hirschhaeuser, F., Sattler, U. G. A., & Mueller-Klieser, W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1457 · Cited by 1,090
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Targeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)
ZHENG, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.928 · Cited by 963
Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
Zhao, H., Yang, L., Baddour, J., Achreja, A., Bernard, V., Moss, T., Marini, J. C., Tudawe, T., Seviour, E. G., San Lucas, F. A., et al. (2016) · eLife · doi:10.7554/elife.10250 · Cited by 927
Ziello, J. E., Jovin, I. S., & Huang, Y. (2007) · PubMed Central · Cited by 895
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Wagner, M., Redaelli, C., Lietz, M., Seiler, C. A., Friess, H., & Büchler, M. W. (2004) · British Journal of Surgery · doi:10.1002/bjs.4484 · Cited by 844
Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821
HIF and c-Myc: Sibling Rivals for Control of Cancer Cell Metabolism and Proliferation
Gordan, J. D., Thompson, C. B., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.006 · Cited by 803
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis: Figure 1
Greijer, A. E., & van der Wall, E. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.015032 · Cited by 784
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770
Glutaminolysis Activates Rag-mTORC1 Signaling
Durán, R. V., Oppliger, W., Robitaille, A. M., Heiserich, L., Skendaj, R., Gottlieb, E., & Hall, M. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.043 · Cited by 730
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Dowling, R. J. O., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726
Hypoxia and Metabolic Adaptation of Cancer Cells
Eales, K. L., Hollinshead, K. E. R., & Tennant, D. A. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.50 · Cited by 724
Metabolic Reprogramming: the Emerging Concept and Associated Therapeutic Strategies
Yoshida, G. J. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0221-y · Cited by 716
DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., & Ellisen, L. W. (2008) · Genes & Development · doi:10.1101/gad.1617608 · Cited by 710
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Kim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Brizel, D. M., Schroeder, T., Scher, R. L., Walenta, S., Clough, R. W., Dewhirst, M. W., & Mueller-Klieser, W. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01630-3 · Cited by 586
de Sousa Cavalcante, L., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 576
Feron, O. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.025 · Cited by 559
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
A Lactate-Induced Response to Hypoxia
Lee, D. C., Sohn, H. A., Park, Z.-Y., Oh, S., Kang, Y. K., Lee, K.-M., Kang, M., Jang, Y. J., Yang, S.-J., Hong, Y. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.011 · Cited by 520
Colell, A., Ricci, J.-E., Tait, S., Milasta, S., Maurer, U., Bouchier-Hayes, L., Fitzgerald, P., Guio-Carrion, A., Waterhouse, N. J., Li, C. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.045 · Cited by 516
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Romero-Garcia, S., Moreno-Altamirano, M. M. B., Prado-Garcia, H., & Sánchez-García, F. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00052 · Cited by 506
Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review
Porporato, P. E., Dhup, S., Dadhich, R. K., Copetti, T., & Sonveaux, P. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00049 · Cited by 425
Kim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., et al. (2008) · Diabetes · doi:10.2337/db07-0381 · Cited by 422
Metabolic control of epigenetics in cancer
Kinnaird, A., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.82 · Cited by 420
Understanding the benefit of metformin use in cancer treatment
Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 409
Haeno, H., Gonen, M., Davis, M. B., Herman, J. M., Iacobuzio-Donahue, C. A., & Michor, F. (2012) · Cell · doi:10.1016/j.cell.2011.11.060 · Cited by 409
Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Ki, K., Hosokawa, M., & Asaka, M. (2001) · PubMed · Cited by 400
Cancer cell metabolism: implications for therapeutic targets
Jang, M., Kim, S. S., & Lee, J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.85 · Cited by 397
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Desai, N., Trieu, V., Damascelli, B., & Soon-Shiong, P. (2009) · Translational Oncology · doi:10.1593/tlo.09109 · Cited by 396
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
Kunkel, M., Reichert, T. E., Benz, P., Lehr, H., Jeong, J., Wieand, S., Bartenstein, P., Wagner, W., & Whiteside, T. L. (2003) · Cancer · doi:10.1002/cncr.11159 · Cited by 390
Favaro, E., Bensaad, K., Chong, M. G., Tennant, D. A., Ferguson, D. J. P., Snell, C., Steers, G., Turley, H., Li, J.-L., Günther, U. L., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.017 · Cited by 386
for the ‘Tumour and Angiogenesis Research Group’, Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Bougioukas, G., Didilis, V, Gatter, K. C., & Harris, A. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601205 · Cited by 377
ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
Friboulet, L., Olaussen, K. A., Pignon, J.-P., Shepherd, F. A., Tsao, M.-S., Graziano, S., Kratzke, R., Douillard, J.-Y., Seymour, L., Pirker, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214271 · Cited by 371
Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 361
Zhang, G., He, P., Tan, H., Budhu, A., Gaedcke, J., Ghadimi, B. M., Ried, T., Yfantis, H. G., Lee, D. H., Maitra, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0209 · Cited by 350
Cancer‐generated lactic acid: a regulatory, immunosuppressive metabolite?
Choi, S. Y. C., Collins, C. C., Gout, P. W., & Wang, Y. (2013) · The Journal of Pathology · doi:10.1002/path.4218 · Cited by 338
Nakano, Y., Tanno, S., Koizumi, K., Nishikawa, T., Nakamura, K., Minoguchi, M., Izawa, T., Mizukami, Y., Okumura, T., & Kohgo, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603559 · Cited by 328
Glycolysis in cancer: A potential target for therapy
Gatenby, R. A., & Gillies, R. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.021 · Cited by 304
Oxidative Stress, Tumor Microenvironment, and Metabolic Reprogramming: A Diabolic Liaison
Fiaschi, T., & Chiarugi, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/762825 · Cited by 302
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
Boudreau, A., Purkey, H. E., Hitz, A., Robarge, K., Peterson, D., Labadie, S., Kwong, M., Hong, R., Gao, M., Del Nagro, C., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2143 · Cited by 280
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 280
Microenvironment and tumor cell plasticity: An easy way out
Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 264
Rozengurt, E., Sinnett-Smith, J., & Kisfalvi, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2229 · Cited by 247
Alfarouk, K. O., Verduzco, D., Rauch, C., Muddathir, A. K., Bashir, A. H. H., Elhassan, G. O., Ibrahim, M. E., Orozco, J. D. P., Cardone, R. A., Reshkin, S. J., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.109 · Cited by 245
Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer
Augoff, K., Hryniewicz-Jankowska, A., & Tabola, R. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.035 · Cited by 241
Bondar, V. M., Sweeney‐Gotsch, B., Andreeff, M., Mills, G. B., & McConkey, D. J. (2002) · PubMed · Cited by 234
Metabolic Dependencies in RAS-Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 224
Erkan, M., Kleeff, J., Esposito, I., Giese, T., Ketterer, K., Büchler, M. W., Giese, N. A., & Friess, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208642 · Cited by 217
Liu, H., Liu, Y., & Zhang, J.-T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0445 · Cited by 216
Palmieri, D., Fitzgerald, D., Shreeve, S. M., Hua, E., Bronder, J. L., Weil, R. J., Davis, S., Stark, A. M., Merino, M. J., Kurek, R., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0234 · Cited by 214
Lisanti, M. P., Martinez-Outschoorn, U. E., Chiavarina, B., Pavlides, S., Whitaker-Menezes, D., Tsirigos, A., Witkiewicz, A. K., Lin, Z., Balliet, R. M., Howell, A., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13370 · Cited by 199
Anderson, M., Marayati, R., Moffitt, R., & Yeh, J. J. (2017) · Oncotarget · doi:10.18632/oncotarget.9760 · Cited by 193
mTOR links oncogenic signaling to tumor cell metabolism
Yecies, J. L., & Manning, B. D. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0726-6 · Cited by 183
Stuart, S. D., Schauble, A., Gupta, S., Kennedy, A. D., Keppler, B. R., Bingham, P. M., & Zachar, Z. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-4 · Cited by 183
Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L. G., Rani, R., Funel, N., Smid, K., Honeywell, R., Boggi, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.681 · Cited by 180
Self-citationKietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176
Promising molecular mechanisms responsible for gemcitabine resistance in cancer
Jia, Y., & Xie, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.07.003 · Cited by 170
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 170
Chen, J., Zhao, S., Nakada, K., Kuge, Y., Tamaki, N., Okada, F., Wang, J., Shindo, M., Higashino, F., Takeda, K., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63924-7 · Cited by 170
Reni, M., Dugnani, E., Cereda, S., Belli, C., Balzano, G., Nicoletti, R., Liberati, D., Pasquale, V., Scavini, M., Maggiora, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1722 · Cited by 170
Lu, C.-W., Lin, S.-C., Chien, C., Lin, S., Lee, C., Lin, B.-W., Lee, J., & Tsai, S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.050 · Cited by 156
The role of the cell–cell interactions in cancer progression
Kaminska, K. H., Szczylik, C. A., Bielecka, Z. F., Bartnik, E., Porta, C., Lian, F., & Czarnecka, A. M. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12408 · Cited by 149
Cai, Z., Zhao, J., Li, J., Peng, D.-N., Wang, X., Chen, T.-L., Qiu, Y.-P., Chen, P.-P., Li, W.-J., Xu, L., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.000661 · Cited by 143
Haas, M., Heinemann, V., Kullmann, F., Laubender, R. P., Klose, C., Bruns, C. J., Holdenrieder, S., Modest, D. P., Schulz, C. U., & Boeck, S. H. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1371-3 · Cited by 140
The sweet trap in tumors: aerobic glycolysis and potential targets for therapy
Yu, L., Chen, X., Wang, L., & Chen, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7676 · Cited by 139
Urayama, S., Zou, W., Brooks, K., & Tolstikov, V. (2010) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4420 · Cited by 137
LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma
Yao, F., Zhao, T., Zhong, C., Zhu, J. J., & Zhao, H. (2012) · Tumor Biology · doi:10.1007/s13277-012-0506-0 · Cited by 135
Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance
Butler, E. B., Zhao, Y., Muñoz‐Pinedo, C., Lu, J., & Tan, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3009 · Cited by 135
Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis
Rattan, R., Fehmi, R.-A., & Munkarah, A. R. (2012) · Journal of Oncology · doi:10.1155/2012/928127 · Cited by 134
Chen, X., Li, L.-Y., Guan, Y.-D., Yang, J., & Cheng, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.47 · Cited by 131
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
Chand, S. N., O’Hayer, K., Blanco, F. F., Winter, J. M., & Brody, J. R. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14951 · Cited by 118
Capello, M., Lee, M., Wang, H., Babel, I., Katz, M. H. G., Fleming, J. B., Maitra, A., Wang, H., Tian, W., Taguchi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv132 · Cited by 111
Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers.
Yang, Y., Liu, H., Li, Z., Zhao, Z., Yip-Schneider, M., Fan, Q., Schmidt, C. M., Chiorean, E. G., Xie, J., Liang Cheng, C., et al. (2011) · PubMed Central · Cited by 109
Recent studies of 5-fluorouracil resistance in pancreatic cancer
Wang, W., Yang, Y., Zhao, Y.-P., Zhang, T.-P., Liao, Q., & Shu, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15682 · Cited by 109
Targeting lactate transport suppressesin vivobreast tumour growth
Morais-Santos, F., Granja, S., Miranda‐Gonçalves, V., Moreira, A. H. J., Queirós, S., Vilaça, J. L., Schmitt, F. C., Longatto‐Filho, A., Paredes, J., Baltazar, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3910 · Cited by 107
IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid
Yabu, M., Shime, H., Hara, H., Saito, T., Matsumoto, M., Seya, T., Akazawa, T., & Inoue, N. (2010) · International Immunology · doi:10.1093/intimm/dxq455 · Cited by 103
Mohammad, G. H., Damink, S. W. M. O., Malagó, M., Dhar, D. K., & Pereira, S. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151635 · Cited by 99
Morten, K., Badder, L. M., & Knowles, H. J. (2013) · The Journal of Pathology · doi:10.1002/path.4159 · Cited by 96
In vivo genetic dissection of tumor growth and the Warburg effect
Wang, C., Purkayastha, A., Jones, K. T., Thaker, S. K., & Banerjee, U. K. (2016) · eLife · doi:10.7554/elife.18126 · Cited by 95
Luo, J., Guo, P., Matsuda, K., Truong, N., Lee, A., Chun, C. L., Cheng, S., & Korc, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1202 · Cited by 93
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Caparello, C., Meijer, L. L., Garajová, I., Falcone, A., Large, T. Y. S. L., Funel, N., Geert Kazemier, M., Peters, G. J., Vasile, E., & Giovannetti, E. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.6987 · Cited by 90
Self-citationNovel drugs that target the metabolic reprogramming in renal cell cancer
van der Mijn, J. C., Panka, D. J., Geissler, A. K., Verheul, H. M. W., & Mier, J. W. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0154-8 · Cited by 87
Duxbury, M. S., Ito, H., Benoit, E., Waseem, T., Ashley, S. W., & Whang, E. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1510 · Cited by 78
Investigational cancer drugs targeting cell metabolism in clinical development
Sborov, D. W., Haverkos, B. M., & Harris, P. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960077 · Cited by 72
The effect of HIF-1α on glucose metabolism, growth and apoptosis of pancreatic cancerous cells.
He, G., Jiang, Y., Zhang, B., & Wu, G. (2014) · PubMed · doi:10.6133/apjcn.2014.23.1.14 · Cited by 70
Golias, T., Papandreou, I., Sun, R. C., Kumar, B., Brown, N. V., Swanson, B. J., Pai, R. K., Jaitin, D. A., Le, Q., Teknos, T. N., et al. (2016) · Scientific Reports · doi:10.1038/srep31146 · Cited by 69
Wang, C., Liu, B., Xu, X., Zhuang, B., Li, H., Yin, J., Cong, M., Xu, W., & Lu, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7073 · Cited by 67
Walker, E. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2224 · Cited by 66
Hwang, J., Hong, J.-Y., Kim, K.-R., Kim, S., Choi, W., Kim, M., Jung, S., Shim, H., Bae, W., Hwang, E. C., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-431 · Cited by 65
Physiological glucose is critical for optimized neuronal viability and AMPK responsiveness in vitro
Kleman, A. M., Yuan, J., Aja, S. M., Ronnett, G. V., & Landree, L. E. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.08.028 · Cited by 64
Glucose metabolic phenotype of pancreatic cancer
Chan, A. K. C., Bruce, J. I. E., & Siriwardena, A. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i12.3471 · Cited by 64
Lyshchik, A. P., Higashi, T., Hara, T., Nakamoto, Y., Fujimoto, K., Doi, R., Imamura, M., Saga, T., & Togashi, K. (2007) · Cancer Investigation · doi:10.1080/07357900701208931 · Cited by 59
Dhayat, S. A., Mardin, W. A., Seggewiß, J., Ströse, A., Matuszcak, C., Hummel, R., Senninger, N. J., Mees, S. T., & Haier, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143755 · Cited by 59
Zhang, Y., Höchster, H. S., Stein, S., & Lacy, J. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0025-y · Cited by 58
Pancreatic cancer microenvironment, to target or not to target?
Carr, R. M., & Fernández-Zapico, M. E. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505948 · Cited by 57
Hypoxia Induced Tumor Metabolic Switch Contributes to Pancreatic Cancer Aggressiveness
Vasseur, S., Tomasini, R., Tournaire, R., & Iovanna, J. (2010) · Cancers · doi:10.3390/cancers2042138 · Cited by 56
Min, J. W., Kim, K. I., Kim, H., Kim, E., Noh, W. C., Jeon, H. B., Cho, D., Oh, J. S., Park, I., Hwang, S., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.041 · Cited by 53
Mapping cancer cell metabolism with 13 C flux analysis: Recent progress and future challenges
Young, J., Duckwall, C., & Murphy, T. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.115422 · Cited by 51
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
Iriana, S., Ahmed, S., Gong, J., Annamalai, A., Tuli, R., & Hendifar, A. E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00099 · Cited by 48
Targeting molecular addictions in cancer
Vivanco, I. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.461 · Cited by 46
Cetinbas, N. M., Sudderth, J., Harris, R. C., Cebeci, A., Negri, G. L., Yilmaz, Ö. H., DeBerardinis, R. J., & Sorensen, P. H. B. (2016) · Scientific Reports · doi:10.1038/srep32606 · Cited by 46
Isozymes of pyruvate kinase from human brain, meningiomas, and malignant gliomas.
Veelen, C. W. M. V., Verbiest, H., Vlug, A. M. C., Rijksen, G., & Staal, G. E. J. (1978) · PubMed · Cited by 45
In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells.
Anderson, K. M., Jajeh, J., Guinan, P., & Rubenstein, M. (2009) · PubMed · Cited by 45
Feng, W., Zhang, Y., Li, G., Zhang, P., Wang, G., & Liu, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023267 · Cited by 42
Fujita, H. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1058 · Cited by 41
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
Lipner, M. B., Marayati, R., Deng, Y., Wang, X., Raftery, L., O’Neil, B. H., & Yeh, J. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147113 · Cited by 35
Genomic alterations in pancreatic cancer and their relevance to therapy
Takai, E., & Yachida, S. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.250 · Cited by 32
Guo, Y., Deng, Y., Li, X., Ning, Y., Lin, X., Guo, S., Chen, M., & Han, M. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162658 · Cited by 29
Belizário, J. E., Sangiuliano, B. A., Pérez-Sosa, M., Neyra, J. M., & Moreira, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00312 · Cited by 29
Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
Yamaguchi, H., Kawazu, M., Yasuda, T., Soda, M., Ueno, T., Kojima, S., Yashiro, M., Yoshino, I., Ishikawa, Y., Sai, E., et al. (2015) · Cancer Science · doi:10.1111/cas.12828 · Cited by 28
Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
Luo, Y., Liu, L., Wu, Y., Singh, K., Su, B., Zhang, N., Liu, X., Shen, Y., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3006 · Cited by 26
Pancreatic cancer: current management and treatment strategies
Gall, T., Tsakok, M., Wasan, H. S., & Jiao, L. R. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-133222 · Cited by 26
Pancreatic cancer: New hopes after first line treatment
Aroldi, F., Bertocchi, P., Savelli, G., Rosso, E., & Zaniboni, A. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.682 · Cited by 24
Adjuvant therapy for pancreas cancer in an era of value based cancer care
Ahn, D. H., Williams, T. M., Goldstein, D. A., El‐Rayes, B. F., & Bekaii‐Saab, T. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.004 · Cited by 18
Cited by
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., Zhao, F., You, L., Wang, W., & Zhao, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01169-7 · Cited by 413
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Thomas, D., & Radhakrishnan, P. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0927-5 · Cited by 396
Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review
Stillhart, C., Vučićević, K., Augustijns, P., Basit, A. W., Batchelor, H., Flanagan, T. R., Gesquiere, I., Greupink, R., Keszthelyi, D., Koskinen, M., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105280 · Cited by 320
Metadata
- Authors
- Grasso, C., Jansen, G., & Giovannetti, E.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 114
- Pages
- 139-152
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2598266532
- Cited by
- 253
- References
- 159
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.